GlaxoSmithKline sharpens ax for 650 job cuts—450 in sales—to channel money toward new launches, R&D

After a business review unveiled in July—and ahead of new challenges—GlaxoSmithKline is sharpening its jobs ax to cut 650 across its U.S. business. On the block are 450 field sales positions, plus another 100 each at its U.S. headquarters in Philadelphia and at a commercial hub in North Carolina.